ライフサイエンスコーパス: diphtheria toxoid

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 f the human CCKB/gastrin receptor coupled to diphtheria toxoid.

2 those who had received at least one dose of diphtheria toxoid.

3 ached to protein carriers such as tetanus or diphtheria toxoids.

4 eness of one, two, or three or more doses of diphtheria toxoid against diphtheria among 40- to 49-yea

5 ination coverage with three or more doses of diphtheria toxoid among adults and children.

6 mmunogenicity and safety of a single dose of diphtheria toxoid among adults, blood samples for detect

7 the complete primary vaccination series with diphtheria toxoid and adults 40-49 years of age were the

8 reduced the interval since the last dose of diphtheria toxoid and improved protection against diphth

9 in the infants and their immune response to diphtheria toxoid and pneumococcal vaccination.

10 nd did not affect infant immune responses to diphtheria toxoid and pneumococcal vaccination.

11 Control and Prevention recommend tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccin

12 ids and acellular pertussis, and tetanus and diphtheria toxoids and acellular pertussis vaccines are

13 us, meningococcal conjugate, and tetanus and diphtheria toxoids and acellular pertussis vaccines.

14 al immunization with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccin

15 recommended that the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap

16 single dose of Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine).

17 In 2012, Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccine was

18 (eg, meningococcal; tetanus toxoid, reduced diphtheria toxoid, and reduced acellular pertussis; and

19 In contrast, the mean anti-diphtheria toxoid antibody response increased with incre

20 nt meningococcal conjugate vaccine that uses diphtheria toxoid as the protein carrier (MCV4-DT).

21 ted a panel of diverse hMAbs that recognized diphtheria toxoid, as well as a variety of recombinant p

22 d W-135) meningococcal vaccine conjugated to diphtheria toxoid at 1 of 3 doses and were monitored for

23 alled in January 1999 because of a subpotent diphtheria toxoid component.

24 ter vaccination with either PRP alone or the diphtheria toxoid conjugate of PRP.

25 he A, C, Y, and W-135 Neisseria meningitidis-diphtheria toxoid conjugate vaccine, when given to healt

26 a C. neoformans serotype D strain 24067 GXM-diphtheria toxoid conjugate.

27 this and other studies, low effectiveness of diphtheria toxoid-containing vaccine was suspected to be

28 e produce a single antigenic type of DT, and diphtheria toxoid continues to be an effective vaccine f

29 ere then conjugated with the carrier protein diphtheria toxoid cross-reactive material (CRM) 197 (DT)

30 otein, including keyhole limpet hemocyanion, diphtheria toxoid cross-reactive material (CRM) 197 (DT)

31 P13 was conjugated to tetanus toxoid (TT) or diphtheria toxoid (DT) and administered subcutaneously i

32 tion) were conjugated to the carrier protein diphtheria toxoid (DT) and used to immunize animals.

33 ), pertactin (Prn), tetanus toxoid (TT), and diphtheria toxoid (DT) were measured using commercially

34 w DC pulsed in vitro with an intact protein (diphtheria toxoid (DT)) produce exosomes that induce, in

35 onjugated to an immunogenic carrier protein, diphtheria toxoid (DT), and formulated in a nanoparticul

36 uvants that have activity on the skin, using diphtheria toxoid (DTx) and tetanus toxoid as model anti

37 han microparticles with two antigens (TT and diphtheria toxoid) entrapped simultaneously.

38 infection, required at least three doses of diphtheria toxoid for reliable protection against diseas

39 ning only 12 aa from GAS, when conjugated to diphtheria toxoid, has been shown to protect mice agains

40 dred fifty samples were studied by ELISA for diphtheria toxoid IgG antibodies to assess the utility o

41 This study suggests that one dose of 2 Lf diphtheria toxoid is highly effective in raising DAT to

42 However, S2 conjugated to diphtheria toxoid is highly immunogenic and induces Abs

43 30 days after immunization with Td (tetanus-diphtheria toxoids; manufactured by Serum Institute of I

44 ]) and to have a time since the last dose of diphtheria toxoid of 3-4 years (3.1 [1.1-9.1]) or 5-7 ye

45 ng Ag derived from allografts, we used CD11c-diphtheria toxoid receptor mice to conditionally ablate

46 egies, the immunogenicity of the tetanus and diphtheria toxoids (Td) vaccine was assessed.

47 idered eligible for vaccination with tetanus-diphtheria toxoids (Td).

48 s documented; (6) neonatal immunization with diphtheria toxoid, tetanus toxoid, and acellular pertuss

49 ria toxoid-tetanus toxoid-pertussis (DTP) or diphtheria toxoid-tetanus toxoid (DT) vaccine, 1 to 3 do

50 Previous studies suggested that tetanus and diphtheria toxoids (TTD and DTD, respectively) contain "

51 f maintaining high levels of age-appropriate diphtheria toxoid vaccination, surveillance, accessible

52 r dose of V-TT CV (n=22) or licensed tetanus-diphtheria toxoid vaccine (Td) (n=10; double-masked desi

53 ings, which showed that protection by the J8-diphtheria toxoid vaccine is Ab-mediated and suggest tha

54 sive adult coverage rates for first doses of diphtheria toxoid vaccine, communication interventions e

55 (92%) had received three or more doses of a diphtheria toxoid vaccine, compared with 72% of case-pat

56 trol strategies, immunogenicity of a tetanus-diphtheria toxoids vaccine (Td) containing 2 limits of f

57 A booster dose of diphtheria-toxoid vaccine given to children in the Russi

58 ontrols had received at least three doses of diphtheria-toxoid vaccine.

59 Td) containing 2 limits of flocculation (Lf) diphtheria toxoid was evaluated.

60 diphtheria toxin reacted with formaldehyde (diphtheria toxoid) was compared to that of diphtheria to

61 coadministered antigens such as tetanus and diphtheria toxoids when applied to the skin.

62 47%) controls had received a booster dose of diphtheria toxoid within the previous 2 years.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。